FDA cleared Takeda’s hepcidin mimetic Mimrylo (rusfertide) for adults with polycythemia vera (PV), following late-phase evidence demonstrating the therapy’s ability to address erythrocytosis in the rare blood cancer. The authorization expands Takeda’s portfolio beyond oncology into hematology support, with the drug positioned as a weekly injectable option for PV patients. The approval also underscores continued regulatory focus on agents that modify iron homeostasis rather than only broad cytoreduction. For PV physicians and payers, Mimrylo’s clearance adds another mechanism to treatment algorithms where hematologic control and safety profiles drive switching decisions, particularly for patients inadequately managed with existing options.